Skip to content

The Effectiveness of Perioperative Intravenous Lidocaine on Opioid Consumption and Postoperative Pain in Total Abdominal Hysterectomy

The Effectiveness of Perioperative Intravenous Lidocaine on Opioid Consumption and Postoperative Pain in Total Abdominal Hysterectomy: A Double-blinded Randomized Controlled Trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20190118004
Enrollment
Unknown
Registered
2019-01-18
Start date
2017-09-03
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lidocaine efficacy still controversy Intravenous lidocaine&#44

Interventions

Lidocaine 1.5 mg/kg upto 10 ml bolus then Lidocaine 2 mg/kg/hr. upto 20 ml Infusion volume rate 20 ml/hr. in surgery and 1 hr after surgery ,same volume of NSS
Experimental Drug,Placebo Comparator No treatment
Lidocaine,saline

Sponsors

Srinakharinwirot university
Lead Sponsor
Srinakharinwirot university
Collaborator

Eligibility

Sex/Gender
Female
Age
30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Female patients Aged 30&#45;65 years BMI < 35 kg/m2 American Society of Anesthesiologists (ASA) physical status I or II Scheduled for elective abdominal hysterectomy with general anesthesia.

Exclusion criteria

Exclusion criteria: Unable to use IV&#45;PCA History of allergy to local anesthetics Severe cardiovascular&#44; respiratory&#44; renal or hepatic disease History of seizure Severe psychiatric medical history Preoperative opioids medication and substance abuse Chronic pain syndromes

Design outcomes

Primary

MeasureTime frame
Morphine Consumption 48 hrs. total dose of morphine that patients press

Secondary

MeasureTime frame
Pain Score 24 hours visual analog scale

Countries

thailand

Contacts

Public ContactRattanaporn Imarom

Department of Anesthesiology&#44; Faculty of Medicine&#44; HRH Princess Maha Chakri Sirindhorn Medical Cente

ีuglyline@hotmail.com0882125108

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026